Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial
The myeloproliferative neoplasm, myelofibrosis, is a morbid and frequently fatal illness encompassing primary myelofibrosis, and end-stage essential thrombocythemia and polycythemia. Bevacizumab (15 mg/kg intravenous (i.v.) every 21 days) was tested in a phase II international trial conduct...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2013-06-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12126 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|